New cancer drug combo tested in asian patients

NCT ID NCT03433898

Completed Disease control Sponsor: Boehringer Ingelheim Source: ClinicalTrials.gov ↗

Summary

This early-phase study tested two new drugs, BI 754091 and BI 754111, in Asian patients with advanced solid tumors that had stopped responding to standard treatments. The main goals were to find the safest and most effective doses of the drugs, both alone and in combination, and to see if they could shrink tumors in specific cancers like lung, stomach, and liver cancer. Researchers closely monitored patients for side effects and how the drugs moved through their bodies.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Asan Medical Center

Seoul, 05505, South Korea
Chang Gung Memorial Hospital(Linkou)

Taoyuan District, 333, Taiwan
Japanese Foundation for Cancer Research

Tokyo, Koto-ku, 135-8550, Japan
Kanagawa Cancer Center

Kanagawa, Yokohama, 241-8515, Japan
NCKUH

Tainan, 70403, Taiwan
National Cancer Center Hospital

Tokyo, Chuo-ku, 104-0045, Japan
National Cancer Center Hospital East

Chiba, Kashiwa, 277-8577, Japan
National Taiwan University Hospital

Taipei, 10002, Taiwan
Saitama Cancer Center

Saitama, Kitaadachi-gun, 362-0806, Japan
Seoul National University Hospital

Seoul, 03080, South Korea
Severance Hospital

Seoul, 03722, South Korea
Shizuoka Cancer Center

Shizuoka, Sunto-gun, 411-8777, Japan
Taipei Veterans General Hospital

Taipei, 11217, Taiwan

Conditions

Explore the condition pages connected to this study.

NEOPLASMS